Analysts have been eager to weigh in on the Healthcare sector with new ratings on ACADIA Pharmaceuticals (ACAD – Research Report), Hims & Hers Health (HIMS – Research Report) and Amylyx Pharmaceuticals Inc (AMLX – Research Report).
ACADIA Pharmaceuticals (ACAD)
In a report released yesterday, Ritu Baral from TD Cowen maintained a Buy rating on ACADIA Pharmaceuticals, with a price target of $35.00. The company’s shares closed last Tuesday at $26.36.
According to TipRanks.com, Baral is a 5-star analyst with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for ACADIA Pharmaceuticals with a $35.35 average price target, implying a 35.8% upside from current levels. In a report issued on February 22, Mizuho Securities also maintained a Buy rating on the stock with a $40.00 price target.
See today’s best-performing stocks on TipRanks >>
Hims & Hers Health (HIMS)
In a report issued on February 26, Vikram Kesavabhotla from Robert W. Baird maintained a Hold rating on Hims & Hers Health, with a price target of $7.00. The company’s shares closed last Tuesday at $13.43.
According to TipRanks.com, Kesavabhotla is a 1-star analyst with an average return of
Currently, the analyst consensus on Hims & Hers Health is a Moderate Buy with an average price target of $13.50, a 9.5% upside from current levels. In a report issued on February 26, Leerink Partners also initiated coverage with a Hold rating on the stock with a $10.00 price target.
Amylyx Pharmaceuticals Inc (AMLX)
Robert W. Baird analyst Joel Beatty maintained a Buy rating on Amylyx Pharmaceuticals Inc on February 26 and set a price target of $37.00. The company’s shares closed last Tuesday at $19.00.
According to TipRanks.com, Beatty is a 5-star analyst with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Amylyx Pharmaceuticals Inc with a $33.80 average price target, representing an 88.8% upside. In a report issued on February 23, H.C. Wainwright also maintained a Buy rating on the stock with a $42.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on ACAD:
